Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
iNtRON Biotechnology, Inc. (048530.KQ)
KRW2,565.00
+65.00 (+2.60%)
KR KOE Healthcare Biotechnology
Address
137, Sagimakgol-ro
Seongnam-si, KR
Seongnam-si, KR
CEO
Seong-Jun Yoon
Website
intron.co.kr
IPO
2011-01-26
ISIN KR7048530000
Description
iNtRON Biotechnology, Inc. is a global developer of biopharmaceutical solutions focused on averting and remedying human ailments. Its development efforts encompass a range of bacteriophage and endoricin-based therapeutics. This company, which has its primary operations in Seongnam-si, South Korea, was established in 1999.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW2,565.00
+65.00 (+2.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
393.5K
Beta
0.04
Float Shares
24.53M
Free Float %
79.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.32% | -3.24% | -21.32% | -35.21% | -16.71% | -7.29% | -27.95% | -60.66% | -86.97% | -90.35% | -25.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,565.00
DCF (Unlevered)
879.84
-65.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.81
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-10.6% Q1'26: +58.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-244.4% Q1'26: -20.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-146.1% Q1'26: -115.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-137.7% Q1'26: -115.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-24.9% Q1'26: -22.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.8% Q1'26: -7.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.57× Q1'26: -0.74× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.22B
est: 14.10B (-27.5%)
|
20.58B
est: 14.10B (+46.0%)
|
8.35B
est: 8.85B (-5.7%)
|
45.43B
est: 36.52B (+24.4%)
|
29.31B
est: 8.94B (+227.8%)
|
14.01B
est: 30.23B (-53.7%)
|
9.59B
est: 30.62B (-68.7%)
|
6.42B
est: 30.77B (-79.1%)
|
5.74B
est: 5.74B (+0.0%)
|
| EBITDA |
-2.04B
est: 2.96B (-169.0%)
|
8.40B
est: 2.96B (+184.1%)
|
465.87M
est: 1.86B (-74.9%)
|
19.80B
est: 7.66B (+158.5%)
|
13.75B
est: 1.88B (+632.7%)
|
13.22B
est: 6.34B (+108.4%)
|
-6.23B
est: 6.43B (-197.0%)
|
-956.88M
est: -2.38B (+59.8%)
|
-5.96B
est: -443.98M (-1,241.9%)
|
| EBIT |
-2.79B
est: 945.56M (-394.7%)
|
7.46B
est: 945.56M (+689.4%)
|
-957.42M
est: 593.48M (-261.3%)
|
18.24B
est: 2.45B (+644.7%)
|
12.21B
est: 599.63M (+1,936.4%)
|
11.65B
est: 2.03B (+474.8%)
|
-8.15B
est: 2.05B (-496.7%)
|
-2.98B
est: -6.56B (+54.5%)
|
-7.90B
est: -1.22B (-545.8%)
|
| Net Income |
-610.38M
est: 2.14B (-128.5%)
|
8.71B
est: 2.14B (+307.3%)
|
-3.19B
est: 2.01B (-258.7%)
|
14.95B
est: 10.95B (+36.5%)
|
9.73B
est: -2.70B (+459.7%)
|
5.71B
est: 1.04B (+449.2%)
|
-9.70B
est: -2.81B (-245.4%)
|
-2.59B
est: -2.95B (+12.3%)
|
-9.26B
|
| SGA |
1.79B
est: 4.56B (-60.8%)
|
2.06B
est: 4.56B (-54.9%)
|
1.66B
est: 2.86B (-42.2%)
|
6.55B
est: 11.82B (-44.5%)
|
7.04B
est: 2.89B (+143.3%)
|
6.80B
est: 9.78B (-30.5%)
|
4.95B
est: 9.91B (-50.1%)
|
1.49B
est: 10.86B (-86.3%)
|
1.67B
est: 2.03B (-17.6%)
|
| EPS |
-20.38
est: 65.00 (-131.4%)
|
290.89
est: 65.00 (+347.5%)
|
-106.43
est: 61.05 (-274.3%)
|
455.00
est: 332.81 (+36.7%)
|
288.42
est: -82.19 (+450.9%)
|
168.38
est: 31.61 (+432.7%)
|
-292.11
est: -85.30 (-242.5%)
|
-78.74
est: -86.47 (+8.9%)
|
-271.16
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.70B
OE per share TTM
-320.36
Owner's Yield
-11.32%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
93.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 26.6K | 0.29% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 24.5K | 0.28% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 18.1K | 0.39% |
| 4 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 319.95 | 0.33% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 534.63 | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-104.00M
Shares Outstanding
30.89M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kyung Won Yoon | Chief Executive Officer & Vice President - Planning & Management | — | — |
| Sang-Hyun Kang | Chief Technology Officer & Vice President - R&D Department | — | male |
| Seong-Jun Yoon | Chief Executive Officer & President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 048530.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
